Thus, epigenomic mechanisms are at the interface between metabolic disorders and inflammation [4] and are implicated in inflammatory processes throughout T2DM development, which occurs when insulin secretion from pancreatic beta cells cannot sufficiently be increased to compensate for insulin resistance. Here, INS is linked to metabolic disease.